Citations

Clear

1794 citation(s) found for "Yu, Stephanie".

Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations
Bayani, Jane , Poncet, Coralie , Crozier, Cheryl , Hopkins, Megan, Uwimana, Aimé Lambert , Cunningham, Carrie, Benstead, Kim , Lago, Lissandra Dal, Korde, Larissa A. , Nilsson, Cecilia , Nowaczyk, Monika, Peeters, Stéphanie , Peric, Aleksandra , Porter, Peggy L. , Schröder, Carolien P., Rubio, Isabel T. , Ruddy, Kathryn J. , Weyngaert, Daniëlle Van den, Deurzen, Carolien HM van, Leeuwen-Stok, Elise van, Vermeij, Joanna , Bartlett, John M.S. , Trinh, Quang M. , Piper, Tammy , Sobol, Monika, Aebi, Stefan , Bögler, Oliver , Hilbers, Florentine , Hedenfalk, Ingrid A. , Linderholm, Barbro Kristina , Martens, John W.M. , Middleton, Lavinia P. , Murray, Melissa P. , Kelly, Catherine M. , Asperen, Christi J. van , Deurzen, Carolien HM van, Winer, Eric P. , Stein, Lincoln , Giordano, Sharon H. , Cardoso, Fátima

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P4-10-03-P4-10-03

10.1158/1538-7445.sabcs19-p4-10-03 Get It

Abstract Introduction: Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers (BC) and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Few studies have examined the genomic landscape of male BCas, with six male BCas included in The Cancer Genome Atlas (TCGA). Familial studies of male BCas have shown genomic changes similar to female BCa, while a larger targeted sequencing study of 59 male breast cancers identified recurrent mutations affecting PIK3CA and GATA3. To date, there is still limited information regarding the genomic landscape of male BCas; particularly in the context of identifying targeted treatments. To reveal genomic changes that characterize male BCas in the context of known cancer driver genes linked to prognosis and targeted agents, we performed a targeted sequencing study on 248 male BCas from the International Male Breast Cancer Program. Methods: 248 primary M0, ER+ve, HER2-ve male BCas enrolled in the Part 1 (retrospective joint analysis) International Male Breast Cancer Program of 1483 patients diagnosed between 1990-2010 (Cardoso et al. Annals of Oncology, 2018) were processed for nucleic acid extraction from formalin-fixed paraffin embedded (FFPE) tissues. Using the Thermo Fisher Scientific Oncomine Comprehensive Assay v3 (OCAv3), a validated targeted sequencing panel currently used in the NCI-MATCH trial (NCT02465060), we evaluated mutational and copy number variations (CNVs) of genes that are prognostic or predictive to targeted therapies currently in use in the clinic or late-stage clinical trials. The OCAv3 DNA pan-cancer panel assays 115 genes for determining mutational status (48 full coding and 67 hotspot) as well as copy-number assessment in 43 genes. The OCAv3 uses Ampliseq-based technology linked to the Oncomine NGS workflow to identify actionable mutations and CNVs Results: Of the 248 samples assayed, 216 passed strict quality control parameters (87.1%). Using the Oncomine NGS workflow, actionable mutations at ≥5% variant allele frequency (VAF) were most frequently identified in PIK3CA (29.2%), BRCA2 (11.1%), NF1 (11.6%), indels in TP53 (10.6%), ATR (5.6%), ATRX (5.1%), indel BRCA2 (5.1%), TP53 point mutations (4.6%), MET (4.6%), ATM (4.6%), NOTCH2 (4.6%), CHEK1 (4.2%), FANCI (4.2%), PTEN (3.2%) with a number of additional genes identified at lower frequencies. Gene amplifications were most frequently detected in MYC (24.5%), FGFR1 (14.8%), CCND1 (12%), FGF3 (9.7%), FGF19 (9.7%), MDM2 (6.5%), CDK4 (1.4%), FGFR3, MDM4, ERBB2 (0.9% each), and FLT3, AR, MYCL, CDK6, IGF1R, FGFR4, KRAS, AKT3 and ESR1 (0.5% each). Although the results here describe the mutations and copy-number changes deemed to be actionable, further analysis of all non-actionable somatic mutations and CNVs will be presented and compared to female BCas previously assayed using the same panel. Conclusion: In this targeted sequencing study of the largest series of male BCas to our knowledge, we have revealed that PIK3CA continues to be a frequently altered gene in both male and female BCas. However, there is an enrichment of mutations in genes related to DNA repair in male BCs. Interestingly, while MYC is commonly amplified in female BCa, a higher frequency of amplified cases were seen in male BCas, in contrast to female BCas. Together with our previously generated transcriptional profiling data in this data set, we believe that both common and unique biological processes comprising male and female BCas will ultimately improve their clinical management and move towards the goal of precision medicine. This work has been funded by the Breast Cancer Research Foundation (BCRF). Citation Format: Jane Bayani, Coralie Poncet, Cheryl Crozier, Quang M Trinh, Megan Hopkins, Aime Lambert Uwimana, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T Rubio, Kathryn J Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien HM van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Lincoln D Stein, Sharon H Giordano, Fatima Cardoso, John MS Bartlett. The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-10-03.
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley, Michael S. , Milgrom, Sarah A. , Dickinson, Michael , Ng, Andrea K. , Roberts, Kenneth B. , Gao, Sarah , Balogh, Alex, Levis, Mario , Casulo, Carla , Stolten, Michael , Specht, Lena , Wright, Christopher M. , Brady, J.L. , Mikhaeel, N. George , Terezakis, Stephanie , Pepa, Roberta Della , Maghfoor, Irfan , Koenig, Julie L. , Jackson, Christopher , Song, Erin J. , Sehgal, Shuchi, Advani, Ranjana H. , Natkunam, Yasodha , Eich, Hans Theodor, Wirth, Andrew, Hoppe, Richard T. , Advani, Ranjana H , Dickinson, Michael , Binkley, Michael Sargent , Specht, Lena , Hoppe, Richard T , Natkunam, Yasodha , Levis, Mario , Rauf, M. Shahzad , Pinnix, Chelsea C. , Tsang, Richard , Ricardi, Umberto , Casulo, Carla , Plastaras, John Peter , Kelsey, Chris R. , Hoppe, Bradford S. , Picardi, Marco , Kirova, Youlia , Akhtar, Saad , Constine, Louis S

Mayo Clinic

Blood | March 25, 2020 | Volume: 135 | Issue: 26 | Pages: 2365-2374

10.1182/blood.2019003877 | PMID 32211877 Get It

Abstract Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n = 257; 46.0%), CMT (n = 184; 32.9%), CT alone (n = 47; 8.4%), observation (n = 37; 6.6%), rituximab and RT (n = 19; 3.4%), and rituximab alone (n = 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P < .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P = .049) and number of involved sites >2 (P = .0006). OS for patients with stage I-II NLPHL was excellent after all treatments.
Functional informed genome‐wide interaction analysis of body mass index, diabetes and colorectal cancer risk
Xia, Zhiyu , Petersen, Paneen S., Qi, Lihong , Kim, Andre E. , Figueiredo, Jane C. , Nan, Hongmei , Berndt, Sonja I. , Casey, Graham , Conti, David V. , Gallinger, Steven , Gauderman, W. James, Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Moreno, Vı́ctor , Murphy, Neil , Nassir, Rami , Rennert, Gad , Wang, Xiaoliang , Woods, Michael O. , Brenner, Hermann , Slattery, Martha L. , Giovannucci, Edward L. , Chang‐Claude, Jenny, Peters, Ulrike , Kim, Andre E , Buchanan, Daniel D , Hoffmeister, Michael , Rennert, Gad , Moreno, Victor , Gunter, Marc J , Brenner, Hermann , Murphy, Neil , Nassir, Rami , Wang, Xiaoliang , Conti, David V , Nan, Hongmei , Su, Yu-Ru , Lin, Yi , Sakoda, Lori C. , Albanes, Demetrius , Bezieau, Stéphane , Bien, Stephanie A. , Buchanan, Daniel D. , Chan, Andrew T. , Drew, David A. , Giles, Graham G. , Jenkins, Mark A. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Newcomb, Polly A. , Ogino, Shuji , Song, Mingyang , Wolk, Alicja , White, Emily E. , Pharoah, Paul D.P. , Hsu, Li , Campbell, Peter T.

Mayo Clinic

Cancer Medicine | March 24, 2020 | Volume: 9 | Issue: 10 | Pages: 3563-3573

10.1002/cam4.2971 | PMID 32207560 Get It

AbstractBackgroundBody mass index (BMI) and diabetes are established risk factors for colorectal cancer (CRC), likely through perturbations in metabolic traits (e.g. insulin resistance and glucose homeostasis). Identification of interactions between variation in genes and these metabolic risk factors may identify novel biologic insights into CRC etiology.MethodsTo improve statistical power and interpretation for gene‐environment interaction (G × E) testing, we tested genetic variants that regulate expression of a gene together for interaction with BMI (kg/m2) and diabetes on CRC risk among 26 017 cases and 20 692 controls. Each variant was weighted based on PrediXcan analysis of gene expression data from colon tissue generated in the Genotype‐Tissue Expression Project for all genes with heritability ≥1%. We used a mixed‐effects model to jointly measure the G × E interaction in a gene by partitioning the interactions into the predicted gene expression levels (fixed effects), and residual G × E effects (random effects). G × BMI analyses were stratified by sex as BMI‐CRC associations differ by sex. We used false discovery rates to account for multiple comparisons and reported all results with FDR <0.2.ResultsAmong 4839 genes tested, genetically predicted expressions of FOXA1 (P = 3.15 × 10−5), PSMC5 (P = 4.51 × 10−4) and CD33 (P = 2.71 × 10−4) modified the association of BMI on CRC risk for men; KIAA0753 (P = 2.29 × 10−5) and SCN1B (P = 2.76 × 10−4) modified the association of BMI on CRC risk for women; and PTPN2 modified the association between diabetes and CRC risk in both sexes (P = 2.31 × 10−5).ConclusionsAggregating G × E interactions and incorporating functional information, we discovered novel genes that may interact with BMI and diabetes on CRC risk.
Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology,
Apovian, Caroline M., Brethauer, Stacy A., Joffe, Aaron M. , Kushner, Robert F. , Lindquist, R R , Pessah‐Pollack, Rachel , Seger, Jennifer, Adams, Stephanie, Cleek, John B., Correa, Riccardo , Figaro, M. Kathleen, Flanders, Karen, Grams, Jayleen , Hurley, Daniel L. , Kothari, Shanu N. , Seger, Michael, Still, Christopher D. , Mechanick, Jeffrey I. , Garvey, William Timothy , Kim, Julie , Lindquist, Richard, Urman, Richard D , Seger, Michael V.

Mayo Clinic

Obesity | March 23, 2020 | Volume: 28 | Issue: 4 | Pages: No page available

10.1002/oby.22719 | PMID 32202076 Get It

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Methods Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. Results New or updated topics in this CPG include: contextualization in an adiposity‐based chronic disease complications‐centric model, nuance‐based and algorithm/checklist‐assisted clinical decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health care arena. There are 85 numbered recommendations that have updated supporting evidence, of which 61 are revised and 12 are new. Noting that there can be multiple recommendation statements within a single numbered recommendation, there are 31 (13%) Grade A, 42 (17%) Grade B, 72 (29%) Grade C, and 101 (41%) Grade D recommendations. There are 858 citations, of which 81 (9.4%) are evidence level (EL) 1 (highest), 562 (65.5%) are EL 2, 72 (8.4%) are EL 3, and 143 (16.7%) are EL 4 (lowest). Conclusions Bariatric procedures remain a safe and effective intervention for higher‐risk patients with obesity. Clinical decision‐making should be evidence based within the context of a chronic disease. A team approach to perioperative care is mandatory, with special attention to nutritional and metabolic issues.
The genetic architecture of the human cerebral cortex
Grasby, Katrina L. , Jahanshad, Neda , Painter, Jodie N. , Colodro‐Conde, Lucía , Bralten, Janita , Hibar, Derrek P. , Lind, Penelope A. , Pizzagalli, Fabrizio , Ching, Christopher R. K. , McMahon, Mary , Shatokhina, Natalia , Zsembik, Leo , Thomopoulos, Sophia I. , Zhu, Alyssa H. , Strike, Lachlan T. , Alhusaini, Saud , Almeida, Marcio , Amlien, Inge K. , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J. , Bernard, Manon , Brouwer, Rachel M. , Buimer, Elizabeth E.L. , Bürger, Christian, Cannon, Dara M. , Chen, Qiang , Cheung, J. , Couvy‐Duchesne, Baptiste , Dale, Anders M. , Dalvie, Shareefa , Araujo, Tânia Kawasaki de , Zubicaray, Greig I. de , Zwarte, Sonja M. C. de , Braber, Anouk den , Doan, Nhat Trung , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Erk, Susanne , Fan, Chun Chieh , Fedko, Iryna O. , Foley, Sonya , Fukunaga, Masaki , Ge, Tian , Giddaluru, Sudheer, Goldman, Aaron L. , Green, Melissa J. , Groenewold, Nynke A. , Grotegerd, Dominik , Gurholt, Tiril P. , Hansell, Narelle K. , Harris, Mathew A., Harrison, Marc , Haswell, Courtney C. , Hauser, Michael A. , Heslenfeld, Dirk J., Ho, New Fei , Hoehn, David , Holleran, Laurena , Hottenga, Jouke‐Jan , Jansen, Iris E. , Jockwitz, Christiane , Karama, Sherif , Kasperavičiūtė, Dalia , Kaufmann, Tobias , Kelly, Sinéad, Kikuchi, Masataka , Klein, Marieke , Knapp, Michael , Knodt, Annchen R. , Krämer, Bernd , Lancaster, T. , Lewis, Lindsay B. , Mathias, Samuel R. , Melzer, Tracy R. , Milaneschi, Yuri , Mirza‐Schreiber, Nazanin , Moreira, José C.V. , Mühleisen, Thomas W. , Müller‐Myhsok, Bertram , Najt, Pablo , Nakahara, Soichiro , Orfanos, Dimitri Papadopoulos , Pitcher, Toni L. , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R. , Redlich, Ronny , Repple, Jonathan , Riedel, Brandalyn C. , Risacher, Shannon L. , Rocha, Cristiane S. , Salminen, Lauren E. , Saremi, Arvin , Schlag, Fenja, Schmaal, Lianne , Secolin, Rodrigo , Shapland, Chin Yang , Shumskaya, Elena , Sønderby, Ida E. , Sprooten, Emma , Tansey, Katherine E. , Teumer, Alexander , Thalamuthu, Anbupalam , Tordesillas‐Gutiérrez, Diana , Turner, Jessica A. , Uhlmann, Anne , Meer, Dennis van der , Donkelaar, Marjolein M. J. van , Eijk, Liza van , Haren, Neeltje E.M. van , Tol, Marie‐José van , Walton, Esther , Wang, Mingyuan, Wardlaw, Joanna M. , Wen, Wei , Whelan, Christopher D. , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing , Yasuda, Clarissa Lin , Zaremba, Dario , Zhang, Zuo , Zwiers, Marcel P. , Artiges, Éric , Assareh, Amelia A., Ayesa‐Arriola, Rosa , Belger, Ayşenil , Brandt, Christine L., Brown, Gregory G. , Cichon, Sven , Curran, Joanne E. , Davies, Gareth E., Degenhardt, Franziska , Dennis, Michelle F. , Dietsche, Bruno, Doherty, Colin P. , Espiritu, Ryan, Gowland, Penny , Häusler, Alexander N. , Heindel, Walter , Ho, Beng‐Choon , Holsboer, Florian , Hosten, Norbert , Jang, MiHyun , Jansen, Andreas , Koops, Sanne, Krug, Axel , Lim, Kelvin O. , Luykx, Jurjen J. , Mather, Karen A. , Mattay, Venkata S. , Son, Jacqueline Mayoral-van , McEwen, Sarah , Melle, Ingrid , Morris, Derek W. , Nöthen, Markus M. , OʼLeary, Daniel S. , Martinot, Marie‐Laure Paillère , Preda, Adrian , Quinlan, Erin Burke , Rasser, Paul E. , Reppermund, Simone , Steen, Vidar M. , Tooney, Paul A. , Torres, Fábio R. , Veltman, Dick J. , Voyvodic, James , White, Tonya , Yamamori, Hidenaga , Adams, Hieab H.H. , Bis, Joshua C. , Debette, Stéphanie , DeCarli, Charles , Fornage, Myriam , Guðnason, Vilmundur , Hofer, Edith , Ikram, M. Arfan , Longstreth, W.T. , Roshchupkin, Gennady V. , Satizábal, Claudia L. , Schmidt, Reinhold, Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Alvim, Marina K. M. , Ames, David, Anderson, Tim , Blangero, John , Brodaty, Henry , Brunner, Han G. , Buckner, Randy L. , Buitelaar, Jan K. , Cairns, Murray J. , Calhoun, Vince D. , Caseras, Xavier , Caspers, Svenja , Cavalleri, Gianpiero L. , Cendes, Fernando , Corvin, Aiden , Crespo‐Facorro, Benedicto , Dalrymple‐Alford, John C. , Geus, Eco J. C. de , Deary, Ian J. , Delanty, Norman, Depondt, Chantal, Desrivières, Sylvane , Donohoe, Gary , Fisher, Simon E. , Flor, Herta , Forstner, Andreas J. , Francks, Clyde , Franke, Barbara , Glahn, David C., Gruber, Oliver , Hariri, Ahmad R. , Hartman, Catharina A. , Hashimoto, Ryota , Heinz, Andreas , Hillegers, Manon H. J. , Hoekstra, Pieter J. , Hong, L. Elliot , Pol, Hilleke E. Hulshoff , Jönsson, Erik G. , Kahn, René S. , Kennedy, Martin A. , Kircher, Tilo , Hellard, Stéphanie Le , Loughland, Carmel M. , Martinot, Jean‐Luc , McMahon, Katie L. , Meyer‐Lindenberg, Andreas , Michie, Patricia T. , Morey, Rajendra A. , Mowry, Bryan , Nyberg, Lars , Oosterlaan, Jaap , Pantelis, Christos , Pausová, Zdenka , Penninx, Brenda W.J.H. , Polderman, Tinca J. C. , Posthuma, Daniëlle , Rowland, Laura M. , Sachdev, Perminder S. , Sämann, Philipp G. , Schall, Ulrich , Schumann, Günter , Scott, Rodney J. , Sim, Kang , Smoller, Jordan W., Sommer, Iris E. , Pourcain, Beaté St , Stein, Dan J. , Ent, Dennis van ‘t , Völzke, Henry , Weber, Bernd , Weinberger, Daniel R. , Wright, Margaret J. , Zhou, Juan , Thompson, Paul M. , Medland, Sarah E. , Seppi, Klaus , Duijn, Cornelia M. van , Jicha, Gregory A. , Vernooij, Meike W. , Mishra, Aniket , Saba, Yasaman , Shenkman, Elizabeth , Ghanbari, Mohsen , Knol, Maria J. , Witte, A. Veronica , Kremen, Sarah , DeCarli, Charles , McMahon, Mary Agnes B , Zsembik, Leo C P , Agartz, Ingrid , Almeida, Marcio A A , Amlien, Inge K , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J , Atkins, Joshua R , Bernard, Manon , Brouwer, Rachel M , Buimer, Elizabeth E L , Chen, Qiang , Cheung, Joshua W , Couvy-Duchesne, Baptiste , Dale, Anders M , de Araujo, Tânia K , de Zubicaray, Greig I , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Fedko, Iryna O , Ford, Judith M , Fukunaga, Masaki , Garrett, Melanie E , Green, Melissa J , Grotegerd, Dominik , Gurholt, Tiril P , Gutman, Boris A , Hansell, Narelle K , Harris, Mathew A , Harrison, Marc B , Haswell, Courtney C , Hauser, Michael , Herms, Stefan , Hoehn, David , Hoffmann, Per , Holleran, Laurena , Hoogman, Martine , Hottenga, Jouke-Jan , Ikeda, Masashi , Janowitz, Deborah , Jansen, Iris E , Jia, Tianye , Jockwitz, Christiane , Kanai, Ryota , Karama, Sherif , Kaufmann, Tobias , Kikuchi, Masataka , Klein, Marieke , Knodt, Annchen R , Krämer, Bernd , Lee, Phil H , Lewis, Lindsay B , Lopes-Cendes, Iscia , Luciano, Michelle , Macciardi, Fabio , Marquand, Andre F , Melzer, Tracy R , Mirza-Schreiber, Nazanin , Moreira, Jose C V , Mühleisen, Thomas W , Najt, Pablo , Olde Loohuis, Loes M , Orfanos, Dimitri Papadopoulos , Pearson, John F , Pitcher, Toni L , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R , Reinbold, Céline S , Repple, Jonathan , Richard, Geneviève , Riedel, Brandalyn C , Rocha, Cristiane S , Mota, Nina Roth , Salminen, Lauren , Saremi, Arvin , Saykin, Andrew J , Schlag, Fenja , Schofield, Peter R , Secolin, Rodrigo , Shapland, Chin Yang , Shen, Li , Shin, Jean , Shumskaya, Elena , Sprooten, Emma , Thalamuthu, Anbupalam , Turner, Jessica A , Vallerga, Costanza Ludovica , van Eijk, Liza , van Erp, Theo G M , van Haren, Neeltje E M , van Rooij, Daan , van Tol, Marie-José , Veldink, Jan H , Verhoef, Ellen , Walton, Esther , Wang, Mingyuan , Wang, Yunpeng , Wardlaw, Joanna Marguerite , Wen, Wei , Westlye, Lars T , Witt, Stephanie H , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing Qin , Yasuda, Clarissa L , Zhang, Zuo , Artiges, Eric , Ayesa-Arriola, Rosa , Belger, Aysenil , Cichon, Sven , Curran, Joanne E , Dennis, Michelle F , Djurovic, Srdjan , Doherty, Colin P , Garijo, Daniel , Gowland, Penny A , Green, Robert C. , Häusler, Alexander N , Ho, Beng-Choon , Hoffmann, Wolfgang U , Holsboer, Florian , Homuth, Georg , Hosten, Norbert , Jack, Clifford R , Jang, MiHyun , Jansen, Andreas , Krug, Axel , Lim, Kelvin O , Luykx, Jurjen J , Mathalon, Daniel H , Mattay, Venkata S , McEwen, Sarah C , Melle, Ingrid , Morris, Derek W , Mueller, Bryon A. , Nordvik, Jan E , Nöthen, Markus M , O'Leary, Daniel S , Preda, Adrian , Rasser, Paul E , Ratnakar, Varun , Steen, Vidar M , Torres, Fábio R , Veltman, Dick J , Voyvodic, James T , Whelan, Robert , Yamamori, Hidenaga , Adams, Hieab H H , López, Oscar L. , Mazoyer, Bernard , Mosley, Thomas H. , Satizabal, Claudia L , Seshadri, Sudha , Alvim, Marina K M , Anderson, Tim J , Andreassen, Ole A , Bastin, Mark E , Beckham, Jean C , Boomsma, Dorret I , Brodaty, Henry , Buitelaar, Jan K , Bustillo, Juan R , Cahn, Wiepke , Cairns, Murray J , Calhoun, Vince D. , Carr, Vaughan J , Cavalleri, Gianpiero L , Corvin, Aiden , Crespo-Facorro, Benedicto , Dalrymple-Alford, John C , Dannlowski, Udo , de Geus, Eco J C , Depondt, Chantal , Desrivières, Sylvane , Donohoe, Gary , Espeseth, Thomas , Fisher, Simon E , Flor, Herta , Francks, Clyde , Franke, Barbara , Gollub, Randy L , Håberg, Asta K , Hartman, Catharina A , Henskens, Frans A , Hillegers, Manon H J , Hoekstra, Pieter J , Holmes, Avram J , Hulshoff Pol, Hilleke E , Jönsson, Erik G , Kennedy, Martin A , Kircher, Tilo T J , Kwok, John B J , Le Hellard, Stephanie , Martin, Nicholas G , McMahon, Katie L , Meyer-Lindenberg, Andreas , Michie, Patricia T , Morey, Rajendra A , Mowry, Bryan , Oosterlaan, Jaap , Ophoff, Roel A , Pantelis, Christos , Pausova, Zdenka , Penninx, Brenda W J H , Polderman, Tinca J C , Posthuma, Danielle , Rietschel, Marcella , Roffman, Joshua L , Sachdev, Perminder S , Schall, Ulrich , Sim, Kang , Sommer, Iris E , St Pourcain, Beate , Stein, Dan J , Toga, Arthur W , Trollor, Julian N , Van der Wee, Nic J A , van 't Ent, Dennis , Walter, Henrik , Weber, Bernd , Weinberger, Daniel R , Wright, Margaret J , Zhou, Juan , Stein, Jason L , Thompson, Paul M , Medland, Sarah E , de Zwarte, Sonja M C , Ching, Christopher R K , Thomopoulos, Sophia I , Cendes, Fernando , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Seppi, Klaus , Hashimoto, Ryota , Jicha, Gregory A , Ge, Tian , Kremen, Sarah , Agartz, Ingrid , Alnæs, Dag , Ashley‐Koch, Allison E. , Bülow, Robin , Bürger, Christian, Chakravarty, M. Mallar , Dohm, Katharina , Lam, Max , Lett, Tristram A. P. , Lopes‐Cendes, Íscia , Nho, Kwangsik T. , Pütz, Benno , Rashid, Faisal M. , Saykin, Andrew J. , Schofield, Peter R. , Shen, Li , Veldink, Jan H. , Witt, Stephanie H. , Gil, Yolanda , Jack, Clifford R. , Kimbrel, Nathan A. , Kolskår, Knut K. , Matthews, Sarah , Nauck, Matthias A. , Opel, Nils , Pike, G. Bruce , Launer, Lenore J. , Mosley, Thomas H. , Seshadri, Sudha , Yang, Qiong , Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Andreassen, Ole A. , Vásquez, Alejandro Arias , Bastin, Mark E. , Baune, Bernhard , Fernández, Guillén , Grabe, Hans Jörgen , Hopkins, William Donald , Jernigan, Terry L. , Kochunov, Peter V , Kwok, John B. , Martin, Nicholas G. , McDonald, Colm , Ophoff, Roel A. , Paus, Tomáš , Sisodiya, Sanjay , Smoller, Jordan W. , Toga, Arthur W. , Walter, Henrik , Stein, Jason L.

Mayo Clinic

Science | March 19, 2020 | Volume: 367 | Issue: 6484 | Pages: No page available

10.1126/science.aay6690 | PMID 32193296 Get It

INTRODUCTION The cerebral cortex underlies our complex cognitive capabilities. Variations in human cortical surface area and thickness are associated with neurological, psychological, and behavioral traits and can be measured in vivo by magnetic resonance imaging (MRI). Studies in model organisms have identified genes that influence cortical structure, but little is known about common genetic variants that affect human cortical structure. RATIONALE To identify genetic variants associated with human cortical structure at both global and regional levels, we conducted a genome-wide association meta-analysis of brain MRI data from 51,665 individuals across 60 cohorts. We analyzed the surface area and average thickness of the whole cortex and 34 cortical regions with known functional specializations. RESULTS We identified 369 nominally genome-wide significant loci ( P < 5 × 10 −8 ) associated with cortical structure in a discovery sample of 33,992 participants of European ancestry. Of the 360 loci for which replication data were available, 241 loci influencing surface area and 66 influencing thickness remained significant after replication, with 237 loci passing multiple testing correction ( P < 8.3 × 10 −10 ; 187 influencing surface area and 50 influencing thickness). Common genetic variants explained 34% (SE = 3%) of the variation in total surface area and 26% (SE = 2%) in average thickness; surface area and thickness showed a negative genetic correlation ( r G = −0.32, SE = 0.05, P = 6.5 × 10 −12 ), which suggests that genetic influences have opposing effects on surface area and thickness. Bioinformatic analyses showed that total surface area is influenced by genetic variants that alter gene regulatory activity in neural progenitor cells during fetal development. By contrast, average thickness is influenced by active regulatory elements in adult brain samples, which may reflect processes that occur after mid-fetal development, such as myelination, branching, or pruning. When considered together, these results support the radial unit hypothesis that different developmental mechanisms promote surface area expansion and increases in thickness. To identify specific genetic influences on individual cortical regions, we controlled for global measures (total surface area or average thickness) in the regional analyses. After multiple testing correction, we identified 175 loci that influence regional surface area and 46 that influence regional thickness. Loci that affect regional surface area cluster near genes involved in the Wnt signaling pathway, which is known to influence areal identity. We observed significant positive genetic correlations and evidence of bidirectional causation of total surface area with both general cognitive functioning and educational attainment. We found additional positive genetic correlations between total surface area and Parkinson’s disease but did not find evidence of causation. Negative genetic correlations were evident between total surface area and insomnia, attention deficit hyperactivity disorder, depressive symptoms, major depressive disorder, and neuroticism. CONCLUSION This large-scale collaborative work enhances our understanding of the genetic architecture of the human cerebral cortex and its regional patterning. The highly polygenic architecture of the cortex suggests that distinct genes are involved in the development of specific cortical areas. Moreover, we find evidence that brain structure is a key phenotype along the causal pathway that leads from genetic variation to differences in general cognitive function. Identifying genetic influences on human cortical structure. ( A ) Measurement of cortical surface area and thickness from MRI. ( B ) Genomic locations of common genetic variants that influence global and regional cortical structure. ( C ) Our results support the radial unit hypothesis that the expansion of cortical surface area is driven by proliferating neural progenitor cells. ( D ) Cortical surface area shows genetic correlation with psychiatric and cognitive traits. Error bars indicate SE. IMAGE CREDITS: (A) K. COURTNEY; (C) M. R. GLASS
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia
Kim, Soyoung , Tecca, Heather R. , Bo‐Subait, Stephanie, Brazauskas, Ruta , Buchbinder, David , Hamilton, Betty K. , Majhail, Navneet S. , Shaw, Peter J. , Marks, David I. , Litzow, Mark R. , Inamoto, Yoshihiro , DeFilipp, Zachariah , Hildebrandt, Gerhard , Olsson, Richard F. , Kasow, Kimberly A. , Rotz, Seth J. , Badawy, Sherif M. , Bhatt, Neel S. , Page, Kristin , Arellano, Martha , Kent, Michael , Farhadfar, Nosha , Seo, Sachiko , Hematti, Peiman , Freytes, César O. , Ganguly, Siddhartha , Nathan, Sunita , Burns, Linda J. , Shaw, Bronwen E. , Muffly, Lori , Olsson, Richard F , Majhail, Navneet S , Badawy, Sherif M , Muffly, Lori , Bhatt, Neel S , Kim, Soyoung , Hematti, Peiman , Lee, Catherine J , Phelan, Rachel , Battiwalla, Minoo , Lazarus, Hillard M. , Chhabra, Saurabh , Liesveld, Jane L. , Yared, Jean A. , Rovó, Alicia

Mayo Clinic

Blood Advances | March 13, 2020 | Volume: 4 | Issue: 6 | Pages: 983-992

10.1182/bloodadvances.2019001126 | PMID 32168378 Get It

Abstract There is marked paucity of data regarding late effects in adolescents and young adults (AYAs) who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). We evaluated late effects and survival in 826 1-year disease-free survivors of MAC HCT for AYA AML, with an additional focus on comparing late effects based upon MAC type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence of subsequent neoplasms was 4% (95% confidence interval [CI], 2%-6%); 10-year cumulative incidence of nonmalignant late effects included gonadal dysfunction (10%; 95% CI, 8%-13%), cataracts (10%; 95% CI, 7%-13%), avascular necrosis (8%; 95% CI, 5%-10%), diabetes mellitus (5%; 95% CI, 3%-7%), and hypothyroidism (3%; 95% CI, 2%-5%). Receipt of TBI was independently associated with a higher risk of cataracts only (hazard ratio [HR], 4.98; P &lt; .0001) whereas chronic graft-versus-host disease (cGVHD) was associated with an increased risk of cataracts (HR, 3.22; P = .0006), avascular necrosis (HR, 2.49; P = .006), and diabetes mellitus (HR, 3.36; P = .03). Estimated 10-year overall survival and leukemia-free survival were 73% and 70%, respectively, and did not differ on the basis of conditioning type. In conclusion, late effects among survivors of MAC HCT for AYA AML are frequent and are more closely linked to cGVHD than type of conditioning.
Evaluating unconscious bias: Speaker introductions at an international oncology conference.
Duma, Narjust , Woods, Cynthia , Fonkoua, Lionel Aurelien Kankeu , Wee, Christopher Eing , González-Vélez, Miguel , Murphy, Martina, Knoll, Miriam A., Durani, Urshila , Cook, Joselle , Fuentes, Harry E , Jain, Shikha , Marshall, Ariela L. , Graff, Stephanie L.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 10503-10503

10.1200/jco.2019.37.15_suppl.10503 Get It

10503 Background: Gender bias can be reinforced through the use of gender-subordinating language and differences in the forms of address. We examined how professional titles were used during speakers’ introductions at the American Society of Clinical Oncology (ASCO) Annual Meeting. Methods: A retrospective observational study of video-archived speaker introductions at the 2017 and 2018 ASCO annual meetings was conducted. Data were extracted by mixed-gender coders. Professional address was defined as professional title followed by full name or last name. Multivariable logistic regressions were used to identify factors associated with the form of address. Results: 2511 videos were reviewed and 812 met inclusion criteria. Regarding speakers’ characteristics, 530 (65%) were non-Hispanic white (NHW), 743 (92%) held a MD or MD-PhD degree, and 484 (60%) were an associate or full professor. Female speakers were less likely to receive a professional address compared to male speakers (61% vs. 81%, p < 0.001). Female speakers were more likely to be introduced by first name only (17% vs. 3%, p < 0.001). Males were less likely to use a professional address when introducing female speakers compared to male speakers (53% vs. 80%, p < 0.01). No gender differences in professional address were observed for female introducers (p = 0.13). Male introducers were more likely to address female speakers by first name only compared to female introducers (24% vs. 7%, p < 0.01). In a multivariable regression including gender, race, degree, and academic rank, male speakers were more likely to receive a professional address compared to female speakers (OR: 2.67, 95%CI: 1.81-3.94, p < 0.01). Black speakers of both genders were less likely to receive a professional address compared to NHW (OR: 0.10, 95%CI: 0.01-0.53, p < 0.01). Female gender was a predictor for a non-professional form of address (first name only) (OR: 9.50, 95%CI: 4.38-20.62, p < 0.01). Conclusions: When introduced by men, female speakers were less likely to receive a professional address and more likely to be introduced by first name only compared to male speakers. Selective use of forms of address may strengthen gender bias; more research is needed to explore the causes of this disparity and its influence.
Current practice for screening and management of financial distress at NCCN member institutions.
Khera, Nandita , Sugalski, Jessica , Krause, Diana, Butterfield, Richard , Zhang, Nan , Smedley, Warren , Stewart, F. Marc, Zafar, Yousuf, Griffin, Joan M. , Zafar, Yousuf, Lee, Stephanie J.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11615-11615

10.1200/jco.2019.37.15_suppl.11615 Get It

11615 Background: Deficiencies and barriers exist to delivering comprehensive and affordable cancer care. Understanding the variation in organizational commitment, existing programs, and expected outcomes for screening and management of financial distress is needed. Methods: Representatives from 17 of 27 NCCN Member Institutions (63%) completed an online survey in November 2018 conducted by the NCCN Best Practices Committee. Centers were classified based on number of unique patients seen per year, as large ( > 10,000) (76%), or small ( < 10,000) (34%). The survey focused on institutions’ screening and management practices for patient financial distress, perceived barriers in implementation, and leadership attitudes. Results: Routine screening for financial distress was reported by 77% of centers, and most used social worker assessments (94%). 56% screened patients throughout the cancer journey. Help with drug costs, meal or gas vouchers and payment plans were offered by 100% of centers. Formal pre-authorization programs and assistance with claims and denials was offered by 81%. Charity care for medical costs was provided by 100% of the large centers compared to only 33% of small centers (p = 0.03). Median number of social workers (24 vs. 3; p = 0.01) and pharmacy representatives (6 vs. 2; p = 0.02) was also different between large and small centers. 76% evaluated the impact of financial advocacy services through number of patients assisted (85%), bad debt and charity write-offs (85%) or patient satisfaction surveys (54%). 6% and 12% reported overall effectiveness of institutional practice for screening and management of financial distress as poor/ very poor respectively. Inadequate staffing and real time resources (69%), limited institutional budget (50%), lack of reimbursement (50%), and clinical time constraints (50%) were reported as potential barriers in provision of these services. 94% agreed about stronger integration of financial advocacy services into oncology practice and 84% felt that success of these services should be a quality metric. 31% of large centers vs. 100% of small centers plan to increase staffing in this area in the next 5 years. Conclusions: Majority of NCCN Member Institutions report screening and management programs for financial distress, though the actual practices and range of services vary widely. Information from this study can help centers benchmark their performance relative to similar cancer programs and identify best practices in this area.
Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.
Scharschmidt, Thomas J. , Black, Jennifer M., Kayton, Mark L. , Okuno, Scott H. , Ostrenga, Andrew , Terezakis, Stephanie , Zambrano, Eduardo , Wang, Dian , Chen, Yen‐Lin , Weiss, Aaron R. , Chi, Yueh‐Yun , Black, Jennifer M., Choy, Edwin , Kao, Simon C. , Randall, R. Lor , Spunt, Sheri L. , Hawkins, Douglas S.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11070-11070

10.1200/jco.2019.37.15_suppl.11070 Get It

11070 Background: Pazopanib is a tyrosine kinase inhibitor approved globally for advanced soft tissue sarcomas. The dose finding phase of this cooperative group trial assessed the dose limiting toxicities (DLT) and the maximally tolerated dose (MTD) of adding pazopanib to neoadjuvant chemoradiation or radiation therapy in children and adults with unresected intermediate/high-risk trunk and extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). Methods: ARST1321, a jointly designed intergroup study lead by Children's Oncology Group and NRG Oncology opened for enrollment in July 2014. Eligible adult and pediatric patients with newly diagnosed, unresected trunk/extremity NRSTS with plans for primary tumor resection were enrolled into either the Chemotherapy Cohort (those with chemosensitive NRSTS > 5 cm, grade 3, including all synovial sarcoma) or the Non-Chemotherapy Cohort (those with chemotherapy insensitive NRSTS of any size, grade 2/3, or any chemosensitive NRSTS for whom no chemotherapy was planned per discretion of patients and treatment teams). In the Chemotherapy Cohort, pazopanib was given with ifosfamide (7.5 grams/m2) and doxorubicin (75 mg/m2) plus 45 Gy preoperative RT starting after cycle 2. Primary tumor was resected at week 13, followed by chemotherapy and pazopanib to week 25. In the Non-Chemotherapy Cohort, pazopanib was given with 50 Gy preoperative RT, primary tumor was resected at week 10, and pazopanib continued to week 25. Feasibility was assessed through week 6 of therapy to determine pazopanib dose escalation/de-escalation based on DLT, total doses of pazopanib, and overall adverse event profile. Results: In the Chemotherapy Cohort, MTD was reached at Dose Level 1 (350 mg/m2 peds; 600 mg adults) with two DLTs (1 grade 3 ALT rise, 1 intolerability to therapy) in 10 patients. In the Non-Chemotherapy Cohort, 11 patients enrolled at Dose Level 1 (350 mg/m2 peds; 600 mg adults) without any observed DLTs and all received ≥75% of prescribed total pazopanib dose; MTD was reached at Dose Level 2 (450 mg/m2 peds; 800 mg adults) with 2 DLTs in ten patients enrolled (1 grade 3 dermatitis and 1 intolerability to therapy) and 9/10 receiving ≥75% of full dose. Conclusions: Pazopanib in combination with chemoradiation or radiation therapy alone was found to be safe in children and adults with NRSTS. Following this finding, ARST1321 opened in both arms using the newly determined pazopanib MTDs. Clinical trial information: NCT02180867.
Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.
Fanburg–Smith, Julie C. , Kayton, Mark L. , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Scharschmidt, Thomas J. , Sorger, Joel, Tian, Jing , Terezakis, Stephanie , Wang, Dian , Zambrano, Eduardo , Black, Jennifer O. , Weiss, Aaron R. , Chi, Yueh‐Yun , Chen, Yen‐Lin , Choy, Edwin , Davis, Jessica L. , Hawkins, Douglas S. , Randall, R. Lor , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11002-11002

10.1200/jco.2019.37.15_suppl.11002 Get It

11002 Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor with activity in advanced soft tissue sarcoma. ARST1321 is a phase II study designed to compare the near complete pathologic response rate (≥ 90% necrosis) of preoperative chemoradiation +/- pazopanib in children and adults with intermediate/high risk chemotherapy-sensitive NRSTS. Methods: ARST1321 is a jointly designed COG and NRG Oncology study opened to enrollment in July 2014. Eligible adult (≥18 years) and pediatric ( < 18 years) patients with unresected, newly diagnosed truncal/extremity NRSTS were enrolled into the Chemotherapy Cohort ( > 5 cm, grade 2/3, protocol-designated chemotherapy-sensitive histology). Following a dose-finding phase, patients were randomized to receive (Regimen A) or not receive (Regimen B) pazopanib ( < 18 years: 350 mg/m2/day; ≥ 18 years: 600 mg/day) in combination with ifosfamide (7.5 gm/m2/cycle) and doxorubicin (75 mg/m2/cycle) + 45 Gy preoperative RT followed by primary resection at week 13, then adjuvant chemotherapy. Results: As of June 30, 2018, 81 eligible patients were enrolled and randomized. Week 13 response is available for 42 patients (60% of expected information). The rate of ≥ 90% pathologic necrosis was 58.3% for Regimen A and 22.2% for Regimen B. Based on the significance level of 0.081 (for the second efficacy analysis with overall one-sided significance level of 0.20, power of 0.80, and O’Brien-Fleming-type cumulative error spending function), the 83.8% confidence interval for the difference was between 16.5% and 55.8%. At this predetermined interim analysis, the efficacy bound was crossed indicating that Regimen A is more efficacious than Regimen B. Given these findings, enrollment was stopped. Grade 3/4 toxicities were 73.8% for Regimen A and 29% for Regimen B with neutropenia, thrombocytopenia and febrile neutropenia being the most common toxicities. Conclusions: The rate of near complete pathologic response was significantly greater with the addition of pazopanib to preoperative chemoradiation in children and adults with intermediate/high risk NRSTS. The comparison of survival outcomes requires longer follow-up. Clinical trial information: NCT02180867.